1 in the alteplase group, five were considered
drug-related).
2 .1 percentage points]); none were considered
drug related.
3 sodes that were considered unintentional and
drug related.
4 patients, respectively; none were considered
drug related.
5 e, secondary to palliative interventions, or
drug related.
6 ients in the oral treatment group; none were
drug related.
7 during the study, but none of the deaths was
drug related.
8 In 5 these were considered
drug related.
9 g the treatment period were considered to be
drug-related.
10 serious adverse events suspected to be study
drug-related.
11 related (0.12 vs 0.22; P = .002), and UC- or
drug-related (
0.14 vs 0.24; P = .005) hospitalizations w
12 ary embolism (grade 4, suspected to be study
drug related)
4 days previously.
13 y of these prognostic scores will reduce non-
drug-related 90-day mortality among patients enrolled in
14 Diarrhea was the most common
drug-related (
93%) and dose-limiting toxicity (DLT), con
15 20 (6%) of 316 participants had study-
drug related adverse events in the tenofovir alafenamide
16 Drug-related adverse effects are manageable in most pati
17 Drug-related adverse effects were infrequent.
18 No serious
drug-related adverse effects were reported; other advers
19 All patients developed grade I
drug-related adverse effects, most commonly muscle spasm
20 ion of patients at risk for poor outcomes or
drug-related adverse effects, will ultimately help to ad
21 ofovir alafenamide discontinued because of a
drug-related adverse event (urticaria) after week 24.
22 open-label ceftriaxone phase, and no serious
drug-related adverse event occurred during the 12-week r
23 The most common
drug-related adverse event was decrease in neutrophil co
24 The most common
drug-related adverse event was headache.
25 The only
drug-related adverse event was hyperglycemia in patients
26 sease progression, 18 (<1%) were caused by a
drug-related adverse event, as assessed by the investiga
27 therapy because of disease progression or a
drug-related adverse event.
28 Fourteen patients had a serious
drug-related adverse event; of these patients, nine perm
29 The most common
drug-related adverse events (> 10% incidence) were nause
30 than for placebo: admissions to hospital for
drug-related adverse events (19 [4%] vs none; p=0.001),
31 vir group than the atazanavir group reported
drug-related adverse events (83 [33%] vs 121 [49%]) or a
32 Higher allergen doses were associated with
drug-related adverse events (AEs), predominantly manifes
33 Five patients (16%) experienced grade 3
drug-related adverse events (AEs); there were no grade 4
34 The most commonly reported
drug-related adverse events (grade 1 or 2) were nausea,
35 Eleven patients (61%) experienced
drug-related adverse events (mostly grade 1-2); none dis
36 The most common
drug-related adverse events (those that occurred in >/=1
37 will continue to monitor device-related and
drug-related adverse events and encourages active survei
38 rug exposure might lessen the possibility of
drug-related adverse events and may also prevent the dev
39 The most common
drug-related adverse events at 5 years in both groups we
40 Incidences of
drug-related adverse events for micafungin and standard
41 Five (1%) participants died because of
drug-related adverse events in the ipilimumab group; thr
42 Common
drug-related adverse events included </= grade 2 hypergl
43 Other common
drug-related adverse events included arm swelling or oed
44 The most common grade >/=3
drug-related adverse events included myelosuppression an
45 No
drug-related adverse events led to treatment discontinua
46 ry tapering or treatment discontinuation for
drug-related adverse events may not only reduce patients
47 Grade 3 to 4
drug-related adverse events more than two-fold higher in
48 A few
drug-related adverse events occurred and were similar ac
49 Drug-related adverse events occurred in 130 (24%) of 531
50 Grade 3 or 4
drug-related adverse events occurred in 14% of patients;
51 Drug-related adverse events occurred in 185 patients (21
52 Drug-related adverse events occurred in 48 patients (98%
53 Drug-related adverse events occurred in 51 (63%) patient
54 Drug-related adverse events of any grade and of grade 3
55 The most common
drug-related adverse events of any grade in the 2 mg/kg
56 Drug-related adverse events of grade 3 or 4 occurred in
57 Drug-related adverse events of grade 3 or 4 were reporte
58 The most common
drug-related adverse events of grade 3 or higher were ne
59 Drug-related adverse events of grade 3 or higher were re
60 associated with an increased risk of serious
drug-related adverse events or mortality.
61 The most frequent
drug-related adverse events overall were neutropenia (28
62 Drug-related adverse events such as asthenia, poor appet
63 Frequency of
drug-related adverse events was comparable between defer
64 Drug-related adverse events were all of mild intensity a
65 Grade 3
drug-related adverse events were common, most frequently
66 No
drug-related adverse events were detected.
67 Common
drug-related adverse events were diarrhea, skin rash, hy
68 The most common
drug-related adverse events were diarrhoea (23/242 [10%]
69 ela in the survivors in either group, and no
drug-related adverse events were documented.
70 The most common
drug-related adverse events were gastrointestinal distur
71 No
drug-related adverse events were identified.
72 The most common grade 3 or 4
drug-related adverse events were increased concentration
73 Grade 3 or 4
drug-related adverse events were infrequent and included
74 All
drug-related adverse events were known toxicities associ
75 Study
drug-related adverse events were less common in the bict
76 as similar between the two groups, but study
drug-related adverse events were more common in the teno
77 le was much the same in each group, although
drug-related adverse events were more common with losmap
78 Drug-related adverse events were mostly grade 1 or 2 and
79 The most common
drug-related adverse events were nausea (39 [7%] vs 18 [
80 The most common study
drug-related adverse events were nausea (in ten particip
81 The most common
drug-related adverse events were nausea (n = 11; 6.6%),
82 The most common
drug-related adverse events were nausea and vomiting.
83 No
drug-related adverse events were noted; procedure-relate
84 The most frequent grade 3 or 4
drug-related adverse events were rash or acne (31 [10%]
85 The most common study
drug-related adverse events were rash, flushing, and dys
86 During the first 12 months of follow-up, 54
drug-related adverse events were reported (51 mild, thre
87 Drug-related adverse events were reported by 13 (41%) of
88 Serious
drug-related adverse events were reported in 108 (43%) p
89 Drug-related adverse events were reported in 109 (42%) p
90 Drug-related adverse events were reported in 130 (98%) p
91 ts remained virologically suppressed, and no
drug-related adverse events were reported.
92 Serious
drug-related adverse events were seen in three patients
93 Common
drug-related adverse events were thrombocytopenia (43%),
94 5 or 60 mg/m(2) The most common grade 3 to 4
drug-related adverse events were thrombocytopenia (47%),
95 Drug-related adverse events were usually of grade 1 or 2
96 The primary endpoint was incidence of
drug-related adverse events, analysed in all randomly as
97 Eighty-eight percent had
drug-related adverse events, including nausea (42%), thr
98 ith 10 (17%) of 60 patients having grade 3-4
drug-related adverse events, the most common of which we
99 in each group discontinued treatment due to
drug-related adverse events.
100 0.56 [95% CI, .41-.75]) but no difference in
drug-related adverse events.
101 Five patients (1%) died due to
drug-related adverse events.
102 There were no differences in serious
drug-related adverse events.
103 Bq and was safe, well tolerated, and without
drug-related adverse events.
104 3%) patients required dose reductions due to
drug-related adverse events.
105 compared with voriconazole, with fewer study-
drug-related adverse events.
106 Four patients discontinued (two because of
drug-related adverse events: elevated liver transaminase
107 injury, Clostridium difficile infection, or
drug-related adverse reactions requiring discontinuation
108 The only possible
drug related AEs reported were dry mouth, dizziness and
109 The most frequently reported
drug-related AEs were micturition urgency (n = 16; 40%),
110 The most common
drug-related AEs with decitabine were thrombocytopenia (
111 se events (AEs), discontinuations because of
drug-related AEs, dose-limiting toxicities, or antidrug
112 The relationship of
drug-related affective sequelae to non-drug reward proce
113 ested for its ability to detect and quantify
drug-related amines.
114 Many hypotensive episodes in the ICU are
drug related and require treatment.
115 forward distinction between exogenous (i.e.,
drug-related)
and endogenous species (as only the radiol
116 tudy because of adverse events (64 [3%] were
drug-related),
as assessed by the investigator, and 171
117 onic cocaine exposure on brain structure and
drug-related behavior in mice.
118 tem, and evidence suggests that it modulates
drug-related behavior.
119 ating HCRT receptor 1 (HCRT-R1) signaling in
drug-related behaviors for all major drug classes, inclu
120 n evaluation of the equivalence of food- and
drug-related behaviors requires a thorough understanding
121 in nucleus accumbens are thought to mediate
drug-related behaviors such as psychomotor sensitization
122 (D2R-MSN) can exert antagonistic effects in
drug-related behaviors, and display distinct alterations
123 bstinence may contribute to these persistent
drug-related behaviors, and identify cocaine exposure as
124 een associated with a variety of smoking and
drug-related behaviors, as well as risk for lung cancer.
125 rage and high levels of state anxiety showed
drug-related BOLD decreases.
126 rders but without the confounding effects of
drug-related brain changes.
127 ss and keratitis), which were not considered
drug related by the respective investigators.
128 When a
drug-related cause was suspected, an objective assessmen
129 to have died of liver cancer (OR = 2.2) and
drug-related causes (OR = 3.1), compared with persons wi
130 ied of liver cancer (odds ratio [OR] = 9.2),
drug-related causes (OR = 4.3), and cirrhosis (OR = 3.7)
131 e range, 2.1-9.1) of follow-up: 18.7% due to
drug-related causes, 55.8% due to HIV-related causes, an
132 For individuals who died of
drug-related causes, longer jail stays were associated w
133 during the first 2 weeks after release (for
drug-related causes, SMR = 8.0, 95% confidence interval
134 ional hypotension was assessed for suspected
drug-related causes.
135 early postrelease period, particularly from
drug-related causes.
136 s of drugs were next analyzed with regard to
drug-related characteristics and their physicochemical p
137 Several patient and
drug-related characteristics contribute to the risk of a
138 l could serve as a biomarker to help predict
drug-related choice--and possibly associated behaviours
139 wo patients in the PGA group exited owing to
drug-related complications (1 patient with uveitis and 1
140 High-risk prescribing and preventable
drug-related complications are common in primary care.
141 One patient in cohort A died of
drug-related complications of immune-related colitis.
142 cause, as well as for UC-related and UC- or
drug-related complications, compared with placebo.
143 le in addictive disorders and is involved in
drug-related craving.
144 ses that used different outcomes (any crime,
drug-related crime, less severe crime, and violent arres
145 These data provide novel insight into
drug-related cross-generational epigenetic effects, and
146 Drug-related cues induce craving, which may perpetuate d
147 We found that exposure to
drug-related cues reinstated cocaine-seeking behavior an
148 Substance abusers have difficulty ignoring
drug-related cues, which is associated with relapse vuln
149 ch relapse is often initiated by exposure to
drug-related cues.
150 ctors for craving and use include stress and
drug-related cues.
151 With increasing availability of
drug-related data, our package will open new avenues of
152 istories of homelessness had higher rates of
drug-related death (RR = 3.4, 95% CI: 2.1, 5.5) and suic
153 ndently protected against HIV-related death,
drug-related death and death due to other causes.
154 e, sex, race, and neighborhood, the risks of
drug-related death and homicide in formerly incarcerated
155 The 90-day mortality was 16.5% with a
drug-related death rate of 0.4%.
156 One
drug-related death was noted.
157 The authors assessed the risks of
drug-related death, suicide, and homicide after release
158 There were four (<1%)
drug-related deaths in the sorafenib group and two (<1%)
159 No
drug-related deaths were observed.
160 No
drug-related deaths were recorded but 16 (62%) patients
161 No
drug-related deaths were reported.
162 es in the 2 mg/kg and 10 mg/kg groups and no
drug-related deaths.
163 There were no
drug-related deaths.
164 basis for a brain-based characterization of
drug-related decision making in drug abuse, including ef
165 Cocaine dependence impacts
drug-related,
dopamine-dependent reward processing, yet
166 ade 3 or higher clinical AEs (1 subject with
drug-related [
DR] psychomotor hyperactivity and insomnia
167 dies are needed to confirm whether this is a
drug-related effect and to determine optimal therapeutic
168 tiation of antiretroviral therapy (ART) when
drug-related effects might offset initial improvements w
169 Although there were no
drug-related effects on peripheral HPA activity, signifi
170 nue using cocaine for reasons beyond desired
drug-related effects.
171 uded discharge functional status and adverse
drug-related effects.
172 verse events that were suspected to be study
drug-related (
eltrombopag: acute kidney injury, arterial
173 If national
drug-related expenditures were applied to heroin users,
174 We found that in addition to
drug-related factors, age and history of diabetes were i
175 Other
drug-related G3 and G4 events included anemia, leukopeni
176 g that transcriptional regulation as well as
drug-related gene expression changes are outcomes of a c
177 openia (42%), fatigue (40%), and rash (40%);
drug-related grade >/=3 events included thrombocytopenia
178 Drug-related grade 3 or 4 adverse events occurred in 15%
179 The most common
drug-related grade 3 or 4 adverse events were neutropeni
180 Significantly more study
drug-related grade 3 or 4 anemia (14.5% v 2.7%), thrombo
181 he 2 mg/kg pembrolizumab group, was the only
drug-related grade 3 to 4 adverse event reported in more
182 Drug-related grade 3 to 4 anemia, fatigue, and neutropen
183 The most frequent
drug-related grade 3-4 adverse events included neutropen
184 ents were regarded by the investigator to be
drug-related (
grade 2 lymphostasis and grade 2 lymphoede
185 o as a "drug-related hazardous condition." A
drug-related hazardous condition is the temporal gap (in
186 s considered drug induced, referred to as a "
drug-related hazardous condition." A drug-related hazard
187 th volasertib experienced more grade 3 and 4
drug-related hematologic adverse events (AEs) and fewer
188 one patient in the gefitinib group died from
drug-related hepatic and renal failure.
189 f palliative cardiac surgery; transfusion or
drug-related hepatitis may also occur.
190 Rates of investigator-assessed
drug-related hepatotoxicity were 0.4% and 2.7%, respecti
191 isease include viral hepatitis coinfections,
drug-related hepatotoxicity, fatty liver disease, and di
192 in risk of all-cause, UC-related, and UC- or
drug-related hospitalizations (by 40%, 50%, and 47%, res
193 itors may offer a unique strategy to prevent
drug-related hypertension and enhance antiangiogenic tum
194 Drug-related improvements in OS were, however, widely di
195 potentially contaminated drug, 741 confirmed
drug-related infections, and 55 deaths.
196 erogeneous network, which integrates diverse
drug-related information.
197 Three patients experienced grade 3 or 4
drug-related infusion-related reactions.
198 tropic glutamate receptors (mGluRs) regulate
drug-related learning, we assayed the consequences of ex
199 A
drug-related linear increase in the amplitude of the fro
200 toxicity are essential to predict unexpected
drug-related liver injury.
201 During transport to the ESI source
drug related material was completely extracted from the
202 sured in the assay (intact drug and/or other
drug related material).
203 Parent drug accounted for 25% of
drug-related material, whereas that of the catabolites [
204 A combined total of 227
drug-related materials (DRM) were detected from all eigh
205 ug addiction is driven, in part, by powerful
drug-related memories.
206 of reconsolidation, causing enhancements of
drug-related memory after retrieval, and significantly c
207 Together, these observations suggest that
drug related modulation of disease relevant brain circui
208 with buprenorphine had reduced all-cause and
drug-related mortality during the first 4 weeks of treat
209 For the remaining time on treatment,
drug-related mortality risk did not differ (adjusted MRR
210 ion, all-cause mortality did not differ, but
drug-related mortality was lower for methadone (adjusted
211 sted all-cause MRR 1.12, 0.79-1.59; adjusted
drug-related MRR 0.50, 0.29-0.86).
212 l-cause MRR 2.17, 95% CI 1.29-3.67; adjusted
drug-related MRR 4.88, 1.73-13.69).
213 erence being driven by a higher incidence of
drug-related nausea in the dolutegravir, abacavir, and l
214 of the alloimmune response, whereas reducing
drug-related nephrotoxicity.
215 Sexual dimorphism in
drug-related neuroanatomic changes and brain-behavior re
216 No cases of paradoxical
drug-related neurological worsening were recorded.
217 reas of research on the subject of toxic and
drug-related neuropathies.
218 The most common
drug-related nonhematologic adverse events were nausea (
219 tment arm, and pleural effusion was the only
drug-related,
nonhematologic adverse event reported more
220 No
drug-related ocular complications were encountered, and
221 self-inflicted injury should be extended to
drug-related or alcohol-related and violent injury in ad
222 girls, and 3.15 [2.73-3.63] for boys) and of
drug-related or alcohol-related death (4.71 [3.28-6.76]
223 tion should address the substantial risks of
drug-related or alcohol-related death alongside risks of
224 Risks of
drug-related or alcohol-related death increased by a sim
225 index injury, risks of suicide and risks of
drug-related or alcohol-related death were increased by
226 ] for girls, and 6.20 [5.27-7.30] for boys),
drug-related or alcohol-related injury (4.55 [3.23-6.39]
227 sks of death in five causal groups (suicide,
drug-related or alcohol-related, homicide, accidental, a
228 dversity-related injury (ie, self-inflicted,
drug-related or alcohol-related, or violent injury) affe
229 following adversity-related (self-inflicted,
drug-related or alcohol-related, or violent injury) or a
230 ar trajectory was associated with all-cause,
drug-related,
or human immunodeficiency virus (HIV)-rela
231 eatment by comparing all-cause mortality and
drug-related overdose mortality at treatment induction,
232 ude mortality rates (CMRs) for all-cause and
drug-related overdose mortality, and mortality rate rati
233 phine reduces mortality risk, especially for
drug-related overdose.
234 iple-therapy group were possibly or probably
drug related (
p=0.007).
235 Grade 1/2
drug-related peripheral neuropathy occurred in 12% (no g
236 ), and thrombocytopenia (five patients, 8%);
drug-related peripheral neuropathy of grade 3 or higher
237 d to exposure to thalidomide only or general
drug-related peripheral neuropathy, we performed a secon
238 antithrombotic therapy emerged as the single
drug-related predictor of GIB in addition to patient-rel
239 nd hospitalizations for an alcohol- or other
drug-related problem (sample 2).
240 Current studies typically use either only
drug-related properties (e.g. chemical structures) or on
241 nced adverse events that were possibly study-
drug related:
pyrexia and intraocular inflammation that
242 onstandardized data extraction methods, only
drug-related quality measures, and no financial incentiv
243 60 patients; one patient developed a grade 3
drug-related rash.
244 erential diagnosis includes lichen planus, a
drug-related reaction, and viral infection.
245 he 10R-allele) show heightened reactivity to
drug-related reinforcement in addiction.
246 atural reward behaviors can alter subsequent
drug-related reward.
247 l cortex associated with the anticipation of
drug-related rewards (cigarette puff).
248 ddiction is associated with overvaluation of
drug-related rewards and undervaluation of natural, nond
249 ction incidence is a surrogate for community
drug-related risk.
250 k force formed to monitor device-related and
drug-related safety events.
251 Third, richer constructs in
drug-related searching.
252 ; 2 withdrew prematurely, 1 because of a non-
drug-related serious adverse event (pharyngitis) and 1 b
253 One
drug-related serious adverse event occurred in a patient
254 No
drug-related serious adverse events (AEs), discontinuati
255 enofovir disoproxil fumarate group had study
drug-related serious adverse events (potential drug-indu
256 We observed no
drug-related serious adverse events after more than 6000
257 We noted grade 3-4
drug-related serious adverse events in 12 (5%) nivolumab
258 rse events occurred in 48 patients (98%) and
drug-related serious adverse events in 17 (35%).
259 Drug-related serious adverse events occurred in 28 (38%)
260 Drug-related serious adverse events occurred in 39 (10%)
261 No other
drug-related serious adverse events occurred.
262 No
drug-related serious adverse events were observed.
263 No
drug-related serious adverse events were reported.
264 No
drug-related serious adverse events were seen.
265 We detected no
drug-related serious adverse events.
266 There were no
drug-related serious adverse events.
267 calcemia, ectopic calcification, or definite
drug-related serious adverse events.
268 There were no
drug-related serious adverse events.
269 AVI-4658 was well tolerated with no
drug-related serious adverse events.
270 tocols but also a potentially higher rate of
drug-related serious adverse events.
271 No
drug-related serious AE was recorded.
272 part 1, 117 adverse events were reported; no
drug-related serious or severe events were reported.
273 ould potentially provide a means of reducing
drug related side effects whilst maintaining, or perhaps
274 Unfortunately, there are strong
drug-related side effects and steroid-refractory patient
275 taging system designation; type and grade of
drug-related side effects; response to treatment; durati
276 Drug-related skin and gastrointestinal disorders of any
277 e ointment treatment arm withdrew because of
drug-related skin irritation.
278 5, 95% confidence interval (CI): 1.14, 1.59;
drug-related SMR: 4.60, 95% CI: 3.17, 6.46; HIV-related
279 lacks specificity when a distinction between
drug-related species and endogenous compounds containing
280 cues translates into an inability to ignore
drug-related stimuli and may reflect deficits in the bra
281 s to fearful stimuli, stressful stimuli, and
drug-related stimuli.
282 se drug craving, particularly in response to
drug-related stimuli.
283 tment is to predict behavioural responses to
drug-related stimuli.
284 advantages for epidemiological, genetic, and
drug-related studies.
285 hange the EV emission profiles reflective of
drug-related therapeutic stress.
286 est that clinical trials of immunomodulatory
drugs related to CTLA4 and that are already Food and Dru
287 tients could switch treatment in the case of
drug-related toxic effects or absence or loss of respons
288 inical recovery and minimizing the effect of
drug-related toxic effects.
289 Drug-related toxicities in 25% to 64% of the 28 patients
290 Other frequent
drug-related toxicities included nausea, stomatitis (bot
291 The most common
drug-related toxicities were diarrhea, nausea, vomiting,
292 Endpoints were the incidence of IFI and
drug-related toxicities.
293 h the combination arm and included one fatal
drug-related toxicity (intestinal occlusion).
294 ot have equivalent susceptibility to serious
drug-related toxicity (SDRT).
295 tion, and no patients experienced antifungal
drug-related toxicity or IFD-associated mortality.
296 demonstrated good tolerability without clear
drug-related toxicity, although the number and duration
297 til disease progression or intolerable study
drug-related toxicity.
298 No
drug-related trends in safety parameters were identified
299 digms of 'simulated' drug choice (choice for
drug-related vs affectively pleasant, unpleasant, and ne
300 Serious adverse events suspected to be study
drug related were reported in eight (11%) patients in th